AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: AZ505 is a small molecule inhibitor that selectively targets the protein lysine methyltransferase SMYD2, with an IC₅₀ of 0.12 μM and high selectivity over related enzymes (IC₅₀ > 83.3 μM for SMYD3, DOT1L, EZH2) (Chen et al., 2023). It functions as a substrate-competitive inhibitor, binding the substrate groove without competing with S-adenosylmethionine (SAM). AZ505 is validated for use in models of cancer and renal fibrosis, where SMYD2 drives disease-related histone and non-histone methylation (see detailed mechanism). APExBIO supplies AZ505 (SKU B1255) for research use, with recommended handling conditions to maximize solubility and stability. Recent studies demonstrate its ability to block epithelial-mesenchymal transition (EMT) and fibrogenic signaling, supporting its utility in epigenetic regulation research (DOI).

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase that methylates histone proteins H2B, H3, and H4 as well as non-histone substrates, including tumor suppressors p53 and Rb (Chen et al., 2023). Aberrant SMYD2 activity is implicated in epigenetic dysregulation, cancer progression, and fibrogenic diseases. SMYD2 overexpression is reported in various cancers, such as gastric cancer and esophageal squamous cell carcinoma (ESCC). In renal fibrosis and chronic kidney disease (CKD), SMYD2 mediates pathological methylation events that drive epithelial-mesenchymal transition (EMT) and fibrogenesis (see lab guide). Targeting SMYD2 with potent and selective inhibitors like AZ505 enables functional studies of methylation pathways and translational exploration of epigenetic therapies.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 functions as a substrate-competitive SMYD2 inhibitor. It binds to the peptide substrate binding groove of SMYD2 and blocks access for histone and non-histone substrates, thereby preventing substrate methylation (Chen et al., 2023). Unlike SAM-competitive inhibitors, AZ505 does not interfere with the methyl donor co-factor S-adenosylmethionine (SAM), maintaining high selectivity. Biochemical assays establish an IC₅₀ of 0.12 μM and a K_i of 0.3 μM for SMYD2 inhibition. Off-target activity against other protein lysine methyltransferases (SMYD3, DOT1L, EZH2) is minimal (IC₅₀ > 83.3 μM). This selectivity is essential for dissecting SMYD2-specific signaling in complex biological systems. The molecular structure and binding kinetics of AZ505 have been characterized in vitro and in cell-based models (mechanistic overview).

Evidence & Benchmarks

• AZ505 strongly inhibits SMYD2-catalyzed methylation of histone H3K36 and non-histone substrates in vitro (IC₅₀ 0.12 μM) (Chen et al., 2023).
• In cisplatin-induced renal fibrosis models, AZ505 administration suppresses SMYD2 expression, reduces EMT markers, and decreases fibrogenic protein levels (Chen et al., 2023, Table 1).
• AZ505 treatment attenuates phosphorylation of pro-fibrotic Smad3 and STAT3, while upregulating the protective factor Smad7 in kidney tissue (Chen et al., 2023, Figure 4).
• AZ505 demonstrates negligible inhibition of related methyltransferases SMYD3, DOT1L, and EZH2 at concentrations up to 83.3 μM, confirming high selectivity (APExBIO product page).
• AZ505 is soluble in DMSO, with recommended warming to 37°C and ultrasonic shaking to enhance dissolution (APExBIO).

Applications, Limits & Misconceptions

AZ505 has become a reference compound for studies of epigenetic regulation, cancer biology, and fibrogenesis. Its high selectivity enables investigation of SMYD2-mediated methylation in disease models, particularly in cancers where SMYD2 is overexpressed (e.g., gastric cancer, ESCC). In renal disease models, AZ505 blocks EMT and fibrosis-related signaling, supporting its value in translational nephrology research (Chen et al., 2023). However, AZ505 is not cell-permeable in all contexts, and off-target effects at high concentrations cannot be ruled out. It is not intended for diagnostic, therapeutic, or clinical use.

This article updates and extends practical guidance from the AZ505 laboratory guide by providing explicit quantitative benchmarks and recent disease model data. For a broader strategic perspective, see AZ505 and the Future of SMYD2 Inhibition, which discusses emergent applications beyond the histone methylation pathway.

Common Pitfalls or Misconceptions

• AZ505 does not inhibit all histone methyltransferases; off-target activity is minimal at recommended concentrations.
• It is not suitable for clinical or diagnostic applications; for research use only (RUO).
• Cell permeability may be limited in some experimental systems—optimization of delivery is advised.
• AZ505 does not reverse established fibrosis or cancer; it modulates methylation-dependent signaling pathways.
• Solubility may decrease at low temperatures; warm and sonicate solutions before use as recommended by APExBIO.

Workflow Integration & Parameters

AZ505 is supplied by APExBIO as SKU B1255 (product page). Stock solutions are prepared in DMSO, with warming to 37°C and ultrasonic shaking to ensure complete dissolution. The compound is stable at -20°C for long-term storage. Typical working concentrations for in vitro assays range from 0.1 to 10 μM, depending on the experimental system and target cell type. For cell-based assays, DMSO concentration should not exceed 0.1% v/v to avoid cytotoxicity. AZ505 is compatible with western blotting, immunoprecipitation, ChIP, and functional readouts of methylation status (see experimental strategies). Researchers should include appropriate negative and positive controls to validate specificity. For disease modeling, AZ505 is typically added prior to or during the induction of fibrogenic or oncogenic signals.

Conclusion & Outlook

AZ505 is a validated, potent, and selective SMYD2 inhibitor that enables precise interrogation of protein lysine methylation in disease models. Peer-reviewed studies confirm its efficacy in blocking SMYD2-dependent events in cancer and renal fibrosis. The substrate-competitive mechanism and high selectivity profile support its use in mechanistic, translational, and drug discovery research. For detailed protocols, quantitative data, and supply, see the APExBIO AZ505 product page. Future work may extend AZ505’s applications to other SMYD2-driven pathologies and inform the next generation of epigenetic modulators.